

## Technology Appraisal Committee Meeting (Committee B)

**Minutes:** Confirmed

**Date and Time:** Thursday 5 May 2016

**Venue:** 10 Spring Gardens  
London  
SW1A 2BU

<b>Present:</b>	1. Dr Amanda Adler (Chair) 2. Dr Sanjeev Patel (Vice-Chair) 3. Professor John Cairns 4. Mr Mark Chapman 5. Dr Mark Glover 6. Dr Neil Iosson 7. Dr Sanjay Kinra 8. Dr Miriam McCarthy 9. Professor Ruairidh Milne 10. Mr Christopher O'Regan 11. Professor John Pounsford 12. Dr Danielle Preedy 13. Mr Alun Roebuck 14. Dr Nigel De-Kare Silver 15. Dr Marta Soares  16. Dr Nicky Welton 17. Mr Nigel Westwood	Present for all notes Present for notes 1 to 17 and notes 29 to 40 Present for all notes Present for all notes
-----------------	---	---

### In attendance:

Meindert Boysen	Programme Director, National Institute for Health and Care Excellence	Present for all notes
Dr Melinda Goodall	Associate Director, National Institute for Health and Care Excellence	Present for all notes
Jeremy Powell	Project Manager, National Institute for Health and Care Excellence	Present for all notes
Marcia Miller	Administrator, National Institute for Health and Care Excellence	Present for all notes

Sophie Laurenson	Technical Analyst, National Institute for Health and Care Excellence	Present for notes 1 to 17
Dr Rosie Lovett	Technical Adviser, National Institute for Health and Clinical Excellence	Present for notes 1 to 17
Jasdeep Hayre	Technical Analyst, National Institute for Health and Care Excellence	Present for notes 18 to 28
Raisa Sidhu	Technical Adviser, National Institute for Health and Clinical Excellence	Present for notes 18 to 40
Helen Tucker	Technical Analyst, National Institute for Health and Care Excellence	Present for notes 29 to 40
Ms Sarah Davis	Senior Lecturer in Health Economics, School of Health and Related Research, University of Sheffield	Present for notes 1 to 15
Mr Rachid Rafia	Research Fellow, School of Health and Related Research, University of Sheffield	Present for notes 1 to 15
Dr Jean Sanderson	Research Associate, School of Health and Related Research, University of Sheffield	Present for notes 1 to 15
Dr Toby Maher	Consultant Respiratory Physician, Royal Brompton Hospital, clinical expert, nominated by Roche	Present for notes 5 to 13
Professor Anna Murphy	Consultant Respiratory Pharmacist, University Hospitals of Leicester NHS Trust, clinical expert, nominated by NHS England	Present for notes 5 to 13
Mr Ronald Flewett	Patient expert, nominated by the Pulmonary Fibrosis Trust	Present for notes 5 to 13
Mr Malcolm Weallans	Treasurer of Pulmonary Fibrosis Trust, patient expert, nominated by the	Present for notes 5 to 13

Ms Kathy Blacker	Pulmonary Fibrosis Trust Regional POC Manager - Accountable Commissioner for Specialised Respiratory CRG, Commissioning expert, nominated by NHS England	Present for notes 5 to 13
Dr Nerys Woolacott	Senior Research Fellow, Centre for Reviews and Dissemination, University of York	Present for notes 18 to 26
Mr Rob Hodgson	Health Economist, Centre for Reviews and Dissemination, University of York	Present for notes 18 to 26
Mr Mousumi Biswas	Research Fellow in Health Economics, Centre for Reviews and Dissemination, University of York	Present for notes 18 to 26
Dr Martin Forster	Clinical Senior Lecturer and Honorary Medical Oncologist, clinical expert, nominated by Pfizer	Present for notes 18 to 26
Professor Andrew Nicholson	Consultant Pathologist & Professor of Respiratory Pathology, clinical expert, nominated by the Royal College of Pathologists	Present for notes 18 to 26
Mrs Carol Davies	Macmillan lung cancer nurse specialist, patient expert, nominated by the National Lung Cancer Forum for Nurses	Present for notes 18 to 26
Dr Jesme Fox	Medical Director, Roy Castle Lung Cancer Foundation, patient expert, nominated by the Roy Castle Lung Cancer Foundation	Present for notes 18 to 26
Professor Matt Stevenson	Technical Director, School of Health and Related Research, University of Sheffield	Present for notes 29 to 37
Dr Inigo Bermejo	Research Associate, School of Health and Related Research, University of Sheffield	Present for notes 29 to 37
Dr Katy Cooper	Senior Research Associate, School of Health and Related	Present for notes 29 to 37

**Non-public observers:**

Helen Barnett Chloe Kastoryano	Medical Editor, NICE Public Involvement Adviser, Patient Involvement Programme, NICE	Present for all notes Present for notes 1 to 28
Heidi Livingstone	Senior Public Involvement Advisor, Patient Involvement Programme, NICE	Present for notes 1 to 28
Edgar Masanga	Business Analyst - Resource Impact Assessment, NICE	Present for notes 1 to 28
Jennifer Dickson	Scottish Medicines Consortium	Present for notes 1 to 28
Lindsay Lockart	Scottish Medicines Consortium	Present for notes 1 to 28
Phil Morgan	Health Economist, Centre for Reviews and Dissemination, University of York	Present for notes 1 to 28

**Notes**

**Welcome**

1. The Chair welcomed all members of the Committee and other attendees present to the meeting. The Chair reviewed the agenda and timescales for the meeting, which included the appraisals of pirfenidone for treating idiopathic pulmonary fibrosis (review of TA282) [ID837], crizotinib for untreated anaplastic lymphoma kinase-positive non-small-cell lung cancer [ID865] and mepolizumab for treating severe eosinophilic asthma [ID798].
2. The Chair informed the Committee of the non-public observers at this meeting: Helen Barnett, Chloe Kastoryano, Heidi Livingstone, Edgar Masanga, Jennifer Dickson, Lindsay Lockart and Phil Morgan.
3. Apologies were received from Dr Ray Armstrong, Dr Jeff Aronson, Anne Joshua, Dr Rebecca Kearney, Professor Stephen Palmer and Professor Ken Stein.

**Any other Business**

4. The Committee were given an update on the progress of other appraisals.

**Appraisal of pirfenidone for treating idiopathic pulmonary fibrosis (review of TA282) [ID837]**

**Part 1 – Open session**

5. The Chair welcomed the invited experts: Ms Sarah Davis, Mr Rachid Rafia, Dr Jean Sanderson, Dr Toby Maher, Professor Anna Murphy, Mr Ronald Flewett, Mr Malcolm Weallans and Ms Kathy Blacker to the meeting and they introduced themselves to the Committee.
6. The Chair welcomed company representatives from Roche to the meeting.
7. The Chair asked all Committee members to declare any relevant interests
  - 7.1. Dr Amanda Adler, Professor John Cairns, Mr Mark Chapman, Dr Mark Glover, Dr Neil Iosson, Dr Sanjay Kinra, Dr Miriam McCarthy, Professor Ruairidh Milne, Mr Christopher O'Regan, Dr Sanjeev Patel, Professor John Poundsford, Dr Danielle Preedy, Mr Alun Roebuck, Dr Nigel De-Kare Silver, Dr Marta Soares, Dr Nicky Welton and Mr Nigel Westwood all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of pirfenidone for treating idiopathic pulmonary fibrosis (review of TA282).
8. The Chair asked all NICE Staff to declare any relevant interests.
  - 8.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of pirfenidone for treating idiopathic pulmonary fibrosis (review of TA282).
9. The Chair asked all other invited guests (assessment group/ERG and invited experts, not including observers) to declare their relevant interests.
  - 9.1. Ms Sarah Davis, Mr Rachid Rafia, Dr Jean Sanderson, Mr Ronald Flewett, Mr Malcolm Weallans and Ms Kathy Blacker declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of pirfenidone for treating idiopathic pulmonary fibrosis (review of TA282).
  - 9.2. Dr Toby Maher declared a personal specific financial interest as he has received consultancy and speaker fees from Roche and Boehringer Ingelheim.
    - 9.2.1. It was agreed that this declaration would not prevent Dr Maher from participating in this section of the meeting
  - 9.3. Professor Anna Murphy declared a personal specific financial interest as she has received speaker fees and attended advisory boards for Roche and Boehringer Ingelheim.
    - 9.3.1. It was agreed that this declaration would not prevent Professor Murphy from participating in this section of the meeting

10. The Chair introduced the lead team, Dr Sanjay Kinra, Mr Mark Chapman and Mr Nigel Westwood who gave presentations on the clinical effectiveness and cost effectiveness of Dr Sanjay Kinra, Mr Mark Chapman and Mr Nigel Westwood.
11. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.
12. The Chair explained that "representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest" (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)" and all public attendees left the meeting.
13. The Chair then thanked the experts and company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

## **Part 2 – Closed session**

14. Discussion on confidential information continued.
15. The Evidence Review Group representatives left the meeting.
16. The Committee continued to discuss the clinical and cost effectiveness of pirfenidone for treating idiopathic pulmonary fibrosis (review of TA282).
  - 16.1. The committee decision was based on consensus.
17. The Committee instructed the technical team to prepare the Appraisal Consultation Document (ACD) in line with their decisions.

## **Appraisal of crizotinib for untreated anaplastic lymphoma kinase-positive non-small-cell lung cancer [ID865]**

### **Part 1 – Open session**

18. The Chair welcomed the invited experts: Dr Nerys Woolacott, Mr Rob Hodgson, Mr Mousumi Biswas, Dr Martin Forster, Professor Andrew Nicholson, Mrs Carol Davies and Dr Jesme Fox to the meeting and they introduced themselves to the Committee.
19. The Chair welcomed company representatives from Pfizer to the meeting.
20. The Chair asked all Committee members to declare any relevant interests
  - 20.1. Dr Amanda Adler, Professor John Cairns, Mr Mark Chapman, Dr Mark Glover, Dr Neil Iosson, Dr Sanjay Kinra, Dr Miriam McCarthy, Professor Ruairidh Milne, Mr Christopher O'Regan, Dr Sanjeev Patel, Professor John Pounsford, Dr Danielle Preedy, Mr Alun Roebuck, Dr Nigel De-Kare Silver, Dr Nicky Welton and Mr Nigel Westwood all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be

considered as part of the appraisal of crizotinib for untreated anaplastic lymphoma kinase-positive non-small-cell lung cancer.

20.2. Dr Marta Soares declared a personal specific financial interest before the meeting as a family member is preparing a submission for Pfizer Portugal on crizotinib in this indication.  
9.2.1 It was agreed that this declaration would prevent Dr Soares from participating in this section of the meeting.

21. The Chair asked all NICE Staff to declare any relevant interests.

21.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of crizotinib for untreated anaplastic lymphoma kinase-positive non-small-cell lung cancer.

22. The Chair asked all other invited guests (assessment group/ERG and invited experts, not including observers) to declare their relevant interests.

22.1. Dr Nerys Woolacott, Mr Rob Hodgson, Mr Mousumi Biswas and Mrs Carol Davies and declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of crizotinib for untreated anaplastic lymphoma kinase-positive non-small-cell lung cancer.

22.2. Dr Martin Forster declared a personal specific financial interest as he is involved in educational and advisory roles for Pfizer, Novartis and Roche and is also involved in several studies with anaplastic lymphoma kinase targeted therapies.  
22.2.1. It was agreed that this declaration would not prevent Dr Forster from participating in this section of the meeting

22.3. Professor Andrew Nicholson declared a personal specific financial interest as he has attended educational and advisory boards for Novartis, Pfizer, AstraZeneca, Roche, Bristol Myers Suibb, Merck and Eli Lilly.  
22.3.1. It was agreed that this declaration would not prevent Professor Nicholson from participating in this section of the meeting

22.4. Dr Jesme Fox declared a personal non specific financial interest as as her employer, The Roy Castle Lung Cancer Foundation (RCLCF) has received grants from multiple pharmaceutical and commercial businesses for specific projects. She has also presented at many conferences and participated in several advisory boards, organised by multiple pharmaceutical companies. The honariria were given to the RCLCF.  
22.4.1. It was agreed that this declaration would not prevent Dr Fox from participating in this section of the meeting

23. The Chair introduced the lead team, Dr Miriam McCarthy, Professor John Cairns and Dr Dani Preedy who gave presentations on the clinical effectiveness and cost

effectiveness of crizotinib for untreated anaplastic lymphoma kinase-positive non-small-cell lung cancer.

24. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.
25. The Chair explained that "representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest" (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)" and all public attendees left the meeting.
26. The Chair then thanked the experts, Evidence Review Group representatives and company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

## **Part 2 – Closed session**

27. The Committee continued to discuss the clinical and cost effectiveness of crizotinib for untreated anaplastic lymphoma kinase-positive non-small-cell lung cancer.
  - 27.1. The committee decision was based on consensus.
28. The Committee instructed the technical team to prepare the Appraisal Consultation Document (ACD) in line with their decisions.

## **Appraisal of mepolizumab for treating severe eosinophilic asthma [ID798]**

### **Part 1 – Open session**

29. The Chair welcomed the invited experts: Professor Matt Stevenson, Dr Inigo Bermejo and Dr Katy Cooper to the meeting and they introduced themselves to the Committee.
30. The Chair welcomed company representatives from GlaxoSmithKline to the meeting.
31. The Chair asked all Committee members to declare any relevant interests
  - 31.1. Dr Amanda Adler, Professor John Cairns, Mr Mark Chapman, Dr Mark Glover, Dr Neil Iosson, Dr Sanjay Kinra, Dr Miriam McCarthy, Professor Ruairidh Milne, Mr Christopher O'Regan, Dr Sanjeev Patel, Professor John Pounsford, Dr Danielle Preedy, Mr Alun Roebuck, Dr Nigel De-Kare Silver, Dr Marta Soares, Dr Nicky Welton and Mr Nigel Westwood all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of mepolizumab for treating severe eosinophilic asthma.
32. The Chair asked all NICE Staff to declare any relevant interests.
  - 32.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial

interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of mepolizumab for treating severe eosinophilic asthma.

33. The Chair asked all other invited guests (assessment group/ERG and invited experts, not including observers) to declare their relevant interests.
  - 33.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of mepolizumab for treating severe eosinophilic asthma.
34. The Chair introduced the key themes arising from the consultation responses to the Appraisal Consultation Document (ACD) received from consultees, commentators and through the NICE website.
35. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.
36. The Chair explained that "representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest" (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)" and all public attendees left the meeting.
37. The Chair then thanked the experts, Evidence Review Group representatives and company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

## **Part 2 – Closed session**

38. The Committee continued to discuss the clinical and cost effectiveness of mepolizumab for treating severe eosinophilic asthma.
  - 38.1. The committee decision was based on consensus.
39. The Committee instructed the technical team to prepare the Appraisal Consultation Document (ACD) in line with their decisions.

## **Date, time and venue of the next meeting**

40. Wednesday 8 June 2016.